Ariana Harari1, Zigui Chen2, Ana Cecilia Rodríguez3, Allan Hildesheim4, Carolina Porras3, Rolando Herrero5, Sholom Wacholder4, Orestis A Panagiotou4, Brian Befano6, Robert D Burk7, Mark Schiffman4. 1. Department of Microbiology and Immunology. 2. Department of Pediatrics. 3. Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica. 4. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville. 5. Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica International Agency for Research on Cancer, World Health Organization, Lyon, France. 6. Information Management Services, Silver Spring, Maryland. 7. Department of Microbiology and Immunology Department of Pediatrics Department of Obstetrics and Gynecology and Women's Health Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
Abstract
BACKGROUND: Results from the Costa Rica Vaccine Trial (CVT) demonstrated partial cross-protection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16 and HPV-18, against HPV-31, -33, and -45 infection and an increased incidence of HPV-51 infection. METHODS: A study nested within the CVT intention-to-treat cohort was designed to assess high-risk HPV variant lineage-specific vaccine efficacy (VE). The 2 main end points were (1) long-term incident infections persisting for ≥2 years and/or progression to high-grade squamous intraepithelial lesions (ie, cervical intraepithelial neoplasia grade 2/3 [CIN 2/3]) and (2) incident transient infections lasting for <2 years. For efficiency, incident infections due to HPV-16, -18, -31, -33, -35, -45, and -51 resulting in persistent infection and/or CIN 2/3 were matched (ratio, 1:2) to the more-frequent transient viral infections, by HPV type. Variant lineages were determined by sequencing the upstream regulatory region and/or E6 region. RESULTS: VEs against persistent or transient infections with HPV-16, -18, -33, -35, -45, and -51 did not differ significantly by variant lineage. As the possible exception, VEs against persistent infection and/or CIN 2/3 due to HPV-31 A/B and HPV-31C variants were -7.1% (95% confidence interval [CI], -33.9% to 0%) and 86.4% (95% CI, 65.1%-97.1%), respectively (P = .02 for test of equal VE). No difference in VE was observed by variant among transient HPV-31 infections (P = .68). CONCLUSIONS: Overall, sequence variation at the variant level does not appear to explain partial cross-protection by the bivalent HPV vaccine.
BACKGROUND: Results from the Costa Rica Vaccine Trial (CVT) demonstrated partial cross-protection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16 and HPV-18, against HPV-31, -33, and -45 infection and an increased incidence of HPV-51 infection. METHODS: A study nested within the CVT intention-to-treat cohort was designed to assess high-risk HPV variant lineage-specific vaccine efficacy (VE). The 2 main end points were (1) long-term incident infections persisting for ≥2 years and/or progression to high-grade squamous intraepithelial lesions (ie, cervical intraepithelial neoplasia grade 2/3 [CIN 2/3]) and (2) incident transient infections lasting for <2 years. For efficiency, incident infections due to HPV-16, -18, -31, -33, -35, -45, and -51 resulting in persistent infection and/or CIN 2/3 were matched (ratio, 1:2) to the more-frequent transient viral infections, by HPV type. Variant lineages were determined by sequencing the upstream regulatory region and/or E6 region. RESULTS: VEs against persistent or transient infections with HPV-16, -18, -33, -35, -45, and -51 did not differ significantly by variant lineage. As the possible exception, VEs against persistent infection and/or CIN 2/3 due to HPV-31 A/B and HPV-31C variants were -7.1% (95% confidence interval [CI], -33.9% to 0%) and 86.4% (95% CI, 65.1%-97.1%), respectively (P = .02 for test of equal VE). No difference in VE was observed by variant among transient HPV-31 infections (P = .68). CONCLUSIONS: Overall, sequence variation at the variant level does not appear to explain partial cross-protection by the bivalent HPV vaccine.
Authors: L F Xi; L A Koutsky; D A Galloway; J Kuypers; J P Hughes; C M Wheeler; K K Holmes; N B Kiviat Journal: J Natl Cancer Inst Date: 1997-06-04 Impact factor: 13.506
Authors: Long Fu Xi; Nancy B Kiviat; Allan Hildesheim; Denise A Galloway; Cosette M Wheeler; Jesse Ho; Laura A Koutsky Journal: J Natl Cancer Inst Date: 2006-08-02 Impact factor: 13.506
Authors: Diane Solomon; Diane Davey; Robert Kurman; Ann Moriarty; Dennis O'Connor; Marianne Prey; Stephen Raab; Mark Sherman; David Wilbur; Thomas Wright; Nancy Young Journal: JAMA Date: 2002-04-24 Impact factor: 56.272
Authors: N D Christensen; J Dillner; C Eklund; J J Carter; G C Wipf; C A Reed; N M Cladel; D A Galloway Journal: Virology Date: 1996-09-01 Impact factor: 3.616
Authors: Robert D Burk; Masanori Terai; Patti E Gravitt; Louise A Brinton; Robert J Kurman; Willard A Barnes; Mitchell D Greenberg; Olympia C Hadjimichael; Leiping Fu; Larry McGowan; Rodrigue Mortel; Peter E Schwartz; Allan Hildesheim Journal: Cancer Res Date: 2003-11-01 Impact factor: 12.701
Authors: M J J Fleury; A Touzé; E Alvarez; G Carpentier; C Clavel; J-F Vautherot; P Coursaget Journal: Arch Virol Date: 2006-03-03 Impact factor: 2.574
Authors: Hanna Bergman; Brian S Buckley; Gemma Villanueva; Jennifer Petkovic; Chantelle Garritty; Vittoria Lutje; Alina Ximena Riveros-Balta; Nicola Low; Nicholas Henschke Journal: Cochrane Database Syst Rev Date: 2019-11-22
Authors: Pascal van der Weele; Martijn Breeuwsma; Robine Donken; Elske van Logchem; Naomi van Marm-Wattimena; Hester de Melker; Chris J L M Meijer; Audrey J King Journal: PLoS One Date: 2019-03-04 Impact factor: 3.240
Authors: Ana Gradissimo; Viswanathan Shankar; Fanua Wiek; Lauren St Peter; Yevgeniy Studentsov; Anne Nucci-Sack; Angela Diaz; Sarah Pickering; Nicolas F Schlecht; Robert D Burk Journal: Viruses Date: 2021-08-05 Impact factor: 5.048